ReviewArteriosclerosis, thrombosis, and vascular biology2012
Niacin in cardiovascular disease: recent preclinical and clinical developments.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Review
- Niacin and Stroke: The Role of Supplementation and Emerging Concepts in Clinical Practice, a Narrative Review.Current issues in molecular biology · 2025Review
- High Concentrations of Circulating 2PY and 4PY-Potential Risk Factor of Cardiovascular Disease in Patients with Chronic Kidney Disease.International journal of molecular sciences · 2025Review
- Regulation of NADMetabolism: clinical and experimental · 2022Review
- GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice.Communications biology · 2021Article
- The Correlation of Dyslipidemia with the Extent of Coronary Artery Disease in the Multiethnic Study of Atherosclerosis.Journal of lipids · 2018Article
- Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule.Journal of the Endocrine Society · 2017Review
- Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.The Journal of clinical investigation · 2015Article
- Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?Medical science monitor : international medical journal of experimental and clinical research · 2015Review
- The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Review
- High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies.Circulation research · 2014Review
- Pharmacotherapies for lipid modification: beyond the statins.Nature reviews. Cardiology · 2013Review
- Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- GPR109A and vascular inflammation.Current atherosclerosis reports · 2013Review
- Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.Expert review of cardiovascular therapy · 2013Review
- Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.PloS one · 2013Article
- Targeting high density lipoproteins in the prevention of cardiovascular disease?Current cardiology reports · 2012Review
- Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.Journal of lipid research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Niacin has been used for more than 50 years in the treatment of cardiovascular disease, although its use has largely been superseded by better-tolerated lipid-modulating interventions. There has been a renewed interest in the HDL-cholesterol raising properties of niacin, with the appreciation that substantial cardiovascular risk remains despite effective treatment of LDL-cholesterol. This coincides with increasing evidence that the complex functional properties of HDL are not well reflected by measurement of HDL-cholesterol alone. In addition to favorable actions on lipoproteins, it is becoming apparent that niacin may also possess lipoprotein independent or pleiotropic effects including the inhibition of inflammatory pathways mediated by its receptor GPR109A, which is expressed by adipocytes and some leukocytes. In this article we consider emerging and prior clinical trial data relating to niacin. We review recent data in respect of mechanisms of action on lipoproteins, which remain complex and incompletely understood. We discuss the recent reports of anti-inflammatory effects of niacin in adipocytes and through bone marrow derived cells and vascular endothelium. These novel observations come at an interesting time, with current imaging and outcome studies leaving outstanding questions on niacin efficacy in statin-treated patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.